Evaluation of X-MAN Standard for EGFR Genotyping Assay
10 May 2012

Mutations in the epidermal growth factor receptor (EGFR) gene correlate with the effectiveness of therapy for the treatment of advanced non‐small cell lung cancer (NSCLC). Patients with an EGFR mutation respond more favourably to tyrosine kinase inhibitor therapy, therefore knowledge of their mutation status will aid in developing an effective first‐line course of treatment. In this application note, Horizon’s X-MAN™ genomic DNA Standard was used in the company’s routine EGFR assay to evaluate how efficiently it detects the exon 19 deletion.

Popular tags in SelectScience

Buying guides

Write a Review

Join the Global SelectScience Community Today! It’s FREE!

Helping you make informed decisions about the latest lab products and technologies:

  • Be the first to learn about new technologies
  • 10,000+ trusted product reviews from your peers
  • Compare 500,000 products and manufacturers
  • Get exclusive buying tips from experts
  • Find solutions fast: 10,000+ Application Notes, Webinars and Videos

Connect with 250,000 scientists... All in one place!

Become a member today!